Innovative Medicine for everyone everywhere



July 2024

ADOCIA

for everyone, everywhere

innovative medicine

EURONEXT (ADOC)

Forward-looking statements

This corporate presentation (the "Presentation") has been prepared by ADOCIA S.A. (the "Company" and, together with its subsidiary, the "Group") and is provided for information purposes only. It is not for promotional use. References herein to the Presentation shall mean and include this document, any oral presentation accompanying this document provided by the Group, any question and answer session following that oral presentation and any further information that may be made available in connection with the subject matter contained herein (together with the information, statements and opinions contained in this Presentation, the "Information").

The Information is provided as of the date of the Presentation only and may be subject to significant changes at any time without notice. The Group does not undertake any obligation to update the Information.

The Information has not been independently verified. Subject to applicable law, none of the Group or its advisors accepts any responsibility whatsoever and makes no representation, warranty or undertaking, express or implied, is made as to the , as to the fairness, accuracy, completeness or appropriateness of the Information

The Presentation contains information on the Group's markets and competitive position, and more specifically, on the size of its markets. This information has been drawn from various sources or from the Group's own estimates. Investors should not base their investment decision on this information.

The Presentation does not purport to contain comprehensive or complete information about the Group and is qualified in its entirety by the business, financial and other information that the Company is required to publish in accordance with the rules, regulations and practices applicable to companies listed on Euronext Paris including in particular the risk factors described in in the most recent Company's Universal Registration Document filed with the French Financial Markets Authority (Autorité des Marchés Financiers), in any other periodic report and in any other press release, which are available free of charge on the websites of the Group (www.adocia.com) and/or the AMF (www.amf-france.org).

The Information contains certain forward-looking statements. These statements are not guarantees of the Group's future performance. These forward-looking statements relate without limitation to the Group's future prospects, developments and marketing strategy and are based on analyses of earnings forecasts and estimates of amounts not yet determinable. Forward-looking statements are subject to a variety of risks and uncertainties as they relate to future events and are dependent on circumstances that may or may not materialize in the future.

Forward-looking statements cannot, under any circumstance, be construed as a guarantee of the Group's future performance as to strategic, regulatory, financial or other matters and the Group's actual performance, including its financial position, results and cash flow, as well as the trends in the sector in which the Group operates, may differ materially from those proposed or reflected in the forward-looking statements contained in the Information.

Even if the Group's performance, including its financial position, results, cash-flows and developments in the sector in which the Group operates were to conform to the forward-looking statements contained in the Presentation, such results or developments cannot be construed as a reliable indication of the Group's future results or developments. The Group does not undertake any obligation to update or to confirm projections or estimates made by analysts or to make public any correction to any prospective information in order to reflect an event or circumstance that may occur after the date of the Presentation.

The Information does not constitute an offer to sell or subscribe or a solicitation to purchase or subscribe for securities, nor shall there be any sale of these securities in the United States or any other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No public offering of securities may be conducted in any member state of the European Economic Area (including France) prior to the publication in the relevant member state of a prospectus that complies with the provisions of Regulation 2017/119.

2

All persons accessing the Information are deemed to agree to all the limitations and restrictions set out above.

Team experienced in developing and licensing innovation



Olivier Soula PhD, MBA

CEO Co-founder

🔿 Avadel





Mathieu-William Gilbert

Chief Operating Officer



Appointed in May 2024



Gérard Soula PhD, MBA President & CBO Co-founder






Jérémy Benattar PharmD, Eng

Head of Marketing Strategy

Potsuka AstraZeneca




Adocia, 20 years developing innovative treatments for metabolic diseases



- Focus: Developing innovative treatments in diabetes and obesity
- Business model: Partnering products and technologies after preclinical/clinical POC
 - 1 product licensed to **Tonghua Dongbao**
 - 1 exclusive negotiation option granted to Sanofi

Focused on innovation, turned towards partnerships




Diabetes and **Obesity**: worldwide chronic pandemics



Cause: an autoimmune-response destroys <u>insulin</u> producing cells (pancreatic β cells)

The body doesn't use properly insulin ("insulin-resistance"). Overtime, the body produces less and less **insulin**. **1.9 billion** are **overweight** or **obese**²


Diabetes is closely linked to **obesity**



ADOC

Adocia is developing unique formulations of these key hormones to improve diabetes and obesity treatments

1. IDF Atlas, 10th Edition, 2021 2. WHO



ADOCI

7

M1Pram Insulin & amylin analogs combination

Addressing the unmet medical need of obesity in insulin-dependent people

The revolution of satiety hormones: 2 complementary classes

GLP-1 The First class		AMYLIN The New class
 Approved treatments T2D 	S S S S S S S S S S S S S S	Missing hormone in T1D due to absence of β cells (secreting insulin & amylin)
✓ Obesity		 Pramlintide, amylin analog approved in 2005 by FDA for T1D and T2D, solely in

× Not approved for T1D

X No efficacy data for T2D taking mealtime insulin


Reasons: Risk of hypoglycemia and hyperglycemia associated with ketosis¹

Technical challenge: combining insulin and pramlintide in a single pen to avoid increasing the number of injections

combination with mealtime insulin

Amylin is the hormone of choice to treat obesity in people taking mealtime insulin

The vicious circle of obesity and insulin-dependent diabetes




Higher insulin need

M1Pram could break this vicious circle for 40 million insulin-dependent people worldwide


9

To address the unmet need of obesity for insulin-dependent individuals, Adocia has developed a unique combination of insulin and amylin



M1Pram is treating obesity by simply replacing the usual mealtime insulin


M1Pram promises the same weight loss performance as obesity drugs but in the unaddressed population




M1Pram generates high expectations from KOLs



"The phase 2 study of M1Pram shows that a single injection with each meal is as easy to use and as efficient as Humalog for glycemic control without increasing the rate of hypoglycemia. In addition, weight control is challenging for T1D patients, potentially limiting glycemic control and adding cardiovascular risk. While reducing insulin requirement, M1Pram improved appetite control and had a beneficial effect on weight, particularly in obese T1D patients. These features support a future role for this combination formulation for T1D."





"This combination has the potential to finally deliver on the promise of pramlintide for a large number of patients."

Prof. Robert Ratner, Georgetown University Washington DC



"The glycemic results with M1Pram (P1b) are quite promising as is the observed weight loss, which is important given the characteristics of the population taking prandial insulin. I look forward to the next series of clinical trials."

Jay S. Skyler, Professor of Medicine, University of Miami Leonard M. Miller School of Medicine




"Remarkably, after only 3 weeks of treatment with M1Pram (P1b), all known pharmacological effects of pramlintide were observed."

Prof. Thomas Pieber, Medical University of Graz, Austria

Medical Advisory Board: Chantal Mathieu, Matt Riddle, Jay Skyler, Orville Koltermann




M1Pram is a potential first-line treatment for people with obesity under intensive insulin therapy



No competitive product has been identified



M1Pram development plan & key value inflexion points



AdoShell[®] Islets

Toward a cure for type 1 diabetes

ADOCI

15






ORLANDO, FL / HYBRID | JUNE 21-24, 2024

AdoShell, a non-fibrotic encapsulation system for human islets transplantation shows promising results for clinical application as a cure for people with Type 1 Diabetes)

Today, cell therapy in diabetes faces several challenges, restricting its use to a few life-threatening cases



Limitations of islets transplant

1. Immunosuppressants to avoid graft rejection is a high safety concern


2. Limited cell availability, sourced from deceased donors

3. iPSCs: risk of uncontrolled development

AdoShell[®] aims to free people with diabetes from insulin injections



AdoShell[®] protects the encapsulated cells from the host's immune system while maintaining their secreting role



Easy and quick implantation/explantation by laparoscopy


Domestic pig





AdoShell[®] Islets has demonstrated immuno-protection and functionality *in vivo*

Transplantation of AdoShell containing allogenic islets in diabetic rat peritoneum at day 0




ADOCT

19

Explantation of the implant at day 132

AdoShell[®] Islet development plan & key value inflection points




Adocia's objective is to partner AdoShell[®] Islets based on preclinical results, as exemplified by recent deals^{*}



*E.G. Vertex x Semma, Vertex x Viacyte, Eli Lilly x Sigilon, Novo Nordisk x Aspect



BC Lispro partnered with Chinese Leader Tonghua Dongbao (THDB)



Data THDB
 June 2022
 Asia and other territories

THDB licenses for Asia to ensure revenue streams BioChaperone[®] Lispro: Phase 3 ongoing



BioChaperone Lispro Ultra-Rapid Insulin

- Better efficacy profile for less hyperglycemia and less hypoglycemia ("Faster-in" / "Faster-out") vs. comparators
- Good tolerance for optimized daily use
- Adapted to pump

- Deal:
 - \$15m (upfront + milestone received)
 - \$30m milestones to come
 - Double-digit royalties ²
- Status: End of Phase 3 clinical program expected in H2 2024, triggering a \$10m milestone payment
- Target: \$1bn mealtime insulin market in China¹

Adocia is looking for partners in the U.S. & U.E.

Licensed for China & other Asian and Middle-East territories 1. Insulin and analogs in China's public medical institutions (2020) 2. Excluding notably but not limited to US, EU, Japan





Financials & Conclusions




Key financials

- Cash position as of June 30, 2024: €10.3m
- Equity line: w. optional 1.7m shares with Vester Finance (extending cash runway to Q3 2025)


EURONEXT

- Indebtedness: €5.6m (PGE debt maturing Aug. 2026)
- Listed on Euronext Paris (ADOC):
- 14.3 million shares
 - Stock price: ~ €6
 - Liquidity: ~110k shares/day (2024.) 0.8% of cap./day
- €97m funds raised & \$135m received from partnerships, since inception



Shareholder ownership June 30, 2024

2024/2025: Major inflexion points potentially transforming value



Notes

		Å
26	ADOCIA	A

Innovative Medicine for everyone everywhere

Thank you for your interest

115 avenue Lacassagne 69003 Lyon – FRANCE Ph.:+33 4 72 610 610 contactinvestisseurs@adocia.com

